Biofourmis is a provider of digital therapeutics and personalized predictive care. Biofourmis discovers, develops and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians, technology to complement pharmacotherapy, and cost-effective solutions for payers.
- Headquarters
- Singapore
- Founded
- 2015
- Leaders
- Kuldeep Singh Rajput
- Initial Funding
- 2019, Series B
- MMV Team
- Anvesh Ramineni
Ryan Collins - Co-investors
- Softbank Vision Fund, Sequoia Capital India, Jianke, EDBI, OpenSpace Ventures, Aviva Ventures, SGInnovate, and Softbank Vision Fund
- Relevant Happenings
- Health AI Startup Biofourmis Hits $1.3 Billion Valuation With Series D FundingBiofourmis receives FDA breakthrough device designation for heart failure “digital therapy”Qure.ai and Biofourmis named in CB Insight’s annual ranking of the most promising digital heath startups in the worldBiofourmis Announces National Rollout of the Biovitals® Hospital@Home™ Platform to Help Deliver Hospital-Level Care in the Home Aligned with New CMS ProgramBiofourmis raises US$100m in Series C round led by SoftBank